Multiple Sclerosis Research Repository

1. “Disease-Modifying Therapies for Relapsing-Remitting and Primary-Progressive Multiple Sclerosis: Effectiveness and Value”: ICER (Institute for Clinical and Economic Review) (FInal Evidence Report: March 6, 2017)

1. “Disease-Modifying Therapies for Relapsing-Remitting and Primary-Progressive Multiple Sclerosis: Effectiveness and Value”: ICER (Institute for Clinical and Economic Review) (FInal Evidence Report: March 6, 2017)

-no statistical difference between dimethyl fumarate and teriflunomide’s effects on disability progression

-no statistical differences between Gilenya and teriflunomide on disability progression

-lack of statistically significant differences between dimethyl fumarate and fingolimod on ARR and disability progression

-ocrelizumab (for RRMS) was not statistically superior to glatiramer acetate in terms of disability progression

-uncertainty regarding long-term outcomes that could not be measured in a 96-week trial

-MS is a chronic disease with disability progression measured over decades, but the current clinical trial evidence base is dominated by trials lasting two years or less, which is insufficient to confidently assess the comparative effectiveness of current MS therapies on disability progression…Randomized trials should be designed comparing active therapies with defined criteria for both treatment failure and subsequent therapy choices following treatment failure with a minimum of 5 years of follow-up

-DMTs’ effect on quality of life measures: generally small

-there is only one small trial of rituximab compared to placebo with no data on disability progression

-the ARR and disability progression for teriflunomide were not significantly different compared with the interferon and glatiramer acetate